Skip to main
  1. Stocks
  2. Globus Medical
  3. Forecast
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 42%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical is viewed favorably because its core spine franchise, strengthened by the 2023 NuVasive merger, remains supported by premium gross margin of 69.5%, adjusted EBITDA margin of 34.3%, and reiterated FY26 EPS of $4.95-5.05 despite a temporary revenue shortfall. The 2025 Nevro acquisition and rapid Enabling Technologies growth, up 24% with units deployed up 73%, add diversification and create upside as delayed launches and rep productivity issues are described as transient rather than demand-driven. With management targeting MSD-HSD growth in 2027 and expecting margin expansion toward the mid-30% range, the company still appears positioned for double-digit EPS power and further free cash flow growth.

Bears say

Globus Medical is facing a negative fundamental setup because its growth thesis depends on successful integration of the NuVasive and Nevro mergers, yet those deals also create meaningful disruption risk and potential revenue dis-synergies. The bear case points to revenue growth slowing to the low-single digits with flat margins, while downside drivers include weaker spine market growth, reimbursement and pricing headwinds, and operating margin compression versus expectations. Additional pressure comes from lower-than-expected Enabling Technologies sales, slower robotic purchasing, and product launches or expansion into trauma, hips, and knees that may take longer to gain traction.

Globus Medical (GMED) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 42% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Globus Medical (GMED) Analyst Forecast & Price Prediction

Get the latest Globus Medical (GMED) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Globus Medical (GMED)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 12 analysts, Globus Medical (GMED) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $94.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $94.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Globus Medical (GMED) Analyst Forecast & Price Prediction

Get the latest Globus Medical (GMED) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Globus Medical (GMED)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover GMED stock data and trends